Navigation Links
Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Date:10/29/2009

year, as part of a combined injectable analgesic market valued in excess of Au$32Million(1).

"We are delighted to partner with Cumberland to bring this important product to a broader, global audience," said Dr. Mal Eutick, President and Chief Executive Officer of Phebra. "Based on data resulting from clinical trials for Caldolor, we believe there is great opportunity to promote widespread usage throughout Australia and New Zealand."

A recently published study in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults," concluded that postoperative patients receiving Caldolor required less narcotic and experienced less pain compared to patients receiving morphine alone. The World Health Organization has recommended a multi-modal approach to pain management, with non-opioid analgesics such as ibuprofen recommended as first-line treatment(2).

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatm
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today reported ... Total revenues for the first quarter ... $136.8 million in the first quarter of 2014. Revenues ... million in royalty and license payments from PDL,s licensees ... net royalty payments from acquired royalty rights and a ...
(Date:5/6/2015)... Inc. (NYSE: LCI ) today reported financial results ... 2015.  For the fiscal 2015 third ... $80.0 million in last year,s third quarter.  Gross profit ... sales, from $56.1 million, or 70% of net sales.  ... from $10.6 million for the fiscal 2014 third quarter.  ...
(Date:5/6/2015)... May 6, 2015 The Parenteral Drug Association ... finalized agreement with Richard M. Johnson to ... "We are very pleased to have Richard Johnson ... Hal Baseman , the Chair of the Board of ... and growth.  Richard has led a strong staff and ...
Breaking Medicine Technology:PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8PDA Extends Richard M. Johnson as President/CEO for Six Additional Years 2
... Indicate Bioequivalent Pharmacokinetics With Reduced Risk,of ... April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, ... company focused on commercializing proprietary product,candidates ... infectious diseases,today announced positive results from ...
... 2007 - Basilea Pharmaceutica Ltd.,(SWX:BSLN) reported today ... severe chronic hand eczema can benefit from,re-treatment ... alitretinoin was found to be effective in ... to topical treatments.,This pivotal trial demonstrated that ...
Cached Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:5/6/2015)... 06, 2015 A quality built chicken coop condo ... yet practical way to raise chickens on a pasture. By ... Condo, it will have a chicken tractor that stands up to ... many years, as it is able to flex to uneven ground ... of the land are fertilized, and it will help provide the ...
(Date:5/6/2015)... The Canton Group is joining Lardarius ... 6th annual charity softball game. The event takes place on ... Stadium. Past years guests include Joe Flacco, John Harbaugh, Ed ... on sale if you are interested in attending. , ... such as SOAR Baltimore and The CollegeBound ...
(Date:5/6/2015)... Animals make just as good friends as they do pets. ... An Ohio veterinarian has been observing this for ... advantages of owning a pet. , “When animals and humans ... there are proven health benefits for people-- including physical, mental ... Animal Medical Center of Streetsboro said. Every May, ...
(Date:5/6/2015)... Anitha Nallari, MD has joined ... Inc. in Columbus, OH. Dr. Nallari will see patients ... in breast cancer, lung cancer, GI and gallbladder cancer, head ... benign hematology. , Dr. Anitha Nallari is Board ... American Board of Internal Medicine. She completed her medical education ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup established ... has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction system ... handheld qPCR is shown to be capable of detecting ... B, C, and E. Coli. This qPCR system has ... over 9 orders of magnitude dynamic range. A ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... test, researcher says, , THURSDAY, Dec. 3 (HealthDay News) -- ... between vitamin D and heart disease. , People with high ... D activation in the body were found to be twice ... heart failure, the study found. , The finding may lead ...
... LONDON, Dec. 3 Chiltern International Limited (Chiltern), a global ... in Europe, the Americas and Asia, today announces the appointment ... Global Quality & Medical Affairs. Dr. Moore is based at ... physician with 15 years of industry experience. Prior to joining ...
... , PASADENA, Calif., Dec. 3 For California,s 3.4 ... one of the most significant threats to not only their ... , "As the recession and market declines have taken their ... shore up their financial safety net with enhanced disability coverage," ...
... , Research could lead ... prevent mutations known to result in cancer and genetic diseases ... for the first time observed the movement of a single ... one. More significantly, they have identified a previously unknown step ...
... ... test – HiFi DNA Tech sues FDA on December 11 for blocking new technology. ... Trumbull, CN (PRWEB) December 2, ... invasive cancer workup procedure, also known as colposcopic biopsy, is harmful and may be ...
... , , NEW YORK, ... human H1N1/09 Type A influenza ("Swine Flu") has reached a ... with at least 6,500 fatalities. Since there is no ... numbers undoubtedly understate the real situation. , ...
Cached Medicine News:Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2
... Vacuum Manifold system for sample processing consists ... a vacuum is applied, a chemical-resistant polypropylene ... convenience in sample handling. The manifold is ... up to 12 samples simultaneously. Loading, washing, ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: